Mexico: Pharma Boardroom Interview

Last Updated: 10 April 2017
Article by Sergio Olivares, Jr.

Sergio Olivares, managing director at Olivares, explains the TPP's impact on the Mexican pharmaceutical industry's dynamism and Olivares' business proposal as a one-stop shop solution to fulfill all its current and future clients' intellectual property needs.

Olivares began as an intellectual property (IP) boutique in 1969 and is today the most frequently awarded IP practice in  Mexico. Could you please give to our international audience an update about the operations of the firm since we met you two years ago?

My father founded Olivares in 1969 with two attorneys and two technical experts. The firm has been steadily growing since its inception and now it is composed by nine partners.

We have been developing and adapting our offering according to our clients' needs. In this sense, 15 years ago, we realized that an increasing number of customers from the pharmaceutical industry were approaching us to help them enforce their patents. More recently, we have expanded our offering into the corporate area taking advantage of the existing synergies with IP. As an example of these new services Olivares is currently working on a couple of initiatives to help its clients to monetize IP rights, particularly patents;  Mexico has a lot of potential in this approach because a lot of national technology is not protected by patents due to the poor knowledge surrounding the need for IP rights.

We are diversifying and enlarging our operations to fulfill the needs of our clients and to keep up the pace with the latest industry trends in our business. Such success in our diversification strategy has been based on the existing synergies in terms of knowledge and procedures of our different divisions. As a consequence, Olivares is perceived as a disruptive firm that is fully capable of offering an integral and one-stop shop solution to its clients.

What have been the main accomplishments of Olivares during the last few years?

Since 2008, because of the global crisis, the world has drastically changed from an economic, social and political standpoint. As a consequence, IP practices have also had to adapt to such dynamism and Olivares has been highly creative in finding new ways to run its operations, being lawyers but also business people.

Some services provided by IP law firms have started to be considered, to a certain extent, as a commodity, especially in areas such as trademark filing, which is a relatively straightforward process. Therefore, we have found ways to add value by being innovative and proactive in our operations as we are changing the services and the way they are delivered. It is a reality that, if you are not able to keep pace with the industry trends, you are in danger of disappearing. So, our biggest accomplishment has been to ensure that our business model changes to remain in line with the latest industry trends and clients' demands.

Olivares quickly became the first law firm in  Mexico to start a life science practice with specialized human resources dedicated full-time to fulfilling the needs of clients in the sector. How strategically important is the healthcare and life sciences industry within your entire business in comparison to the rest of the industry groups that you are serving such as IT, media and sports & entertainment?

Olivares has moved to different industries, creating one-stop shop solutions in all the areas in which we are active. We have been able to disrupt the classic legal firms approach and this strategy has been reflected in our operations. We have focused our efforts on promoting our new diversified and co-related areas.

With this being said, healthcare and life sciences are highly related to IP services, which is our historical business line. Indeed, our healthcare and life sciences division represents around 50 percent of our total revenues with a particularly strong demand for patents, regulatory and litigation services. Note that in pharma, chemicals, agribusiness, medical devices and other life sciences we estimate to make up around 30 percent of all patents. These sectors, and primarily the pharma sector, makes up 50 percent of all patent litigation in the country, and we are true experts in both patent related litigation and also, importantly, administrative litigation, which is of course an ever-evolving area of law.

What is your footprint in the pharma and medtech industry?

We represent the world's leading innovator companies and have helped them establish stronger IP rights in  Mexico than any other law firm or consulting firm has done. This is of course a big statement, but we can easily back it up with the successful initiatives that we have undertaken over the past decade. Two examples are our highly successful litigation strategies, that have taken literally a decade to come to fruition, that established patent linkage regulations in  Mexico and that are in line with the provisions laid out in international treaties such as the NAFTA agreement. Furthermore, we have worked tirelessly to gain legal precedent to extend the terms for data exclusivity rights. We are registered lobbyists with the Mexican congress (the only IP firm in  Mexico to be so) and we represent AMIIF (the Mexican Association of Pharmaceutical Research Industries), the lobbying group for innovator pharma companies doing business in  Mexico. They trust us enough to have Alejandro Luna represent them in the many rounds of the TPP negotiations.

We believe we have done more than any other firm in  Mexico for this industry, and are proud to serve a large number of the innovator companies in their fight against regulations and the generics market.

Mexico ranks 7th  in Latin American and the Caribbean –behind Chile and Brazil— and 54thworldwide in the 2014 International Property Rights Index. As an expert in this area, what are the major challenges that you and your clients are currently facing from an IP perspective?

The path of development to continue enhancing the Mexican intellectual property framework is to maximize the standards of IP protection. Furthermore,  Mexico is currently in the process of entering the Trans-Pacific Partnership (TPP) and, referring to IP protection, it will create some new challenges because the standards requested are higher. It is perceived that  Mexico will sign individual agreements that are copies of the TPP agreement, with various countries that were involved in the TPP negotiations, regardless of whether the United States signs or not. This in turn will put more pressure on the government to modify IP related regulations so that Mexico meets its obligations to provide a regulatory system that meets the standards of these provisions.

Mexico's IP law has not undergone relevant changes since 1994, when it was amended for the implementation of the North-American Free Trade Agreement (NAFTA). Today Mexico has the opportunity to update it, as  it belongs to the Trans-Pacific Partnership (TPP) with countries throughout the Asia-Pacific region, which imply important issues in regard to the IP protection. As the leading law firm in this area in  Mexico, what are your conclusions on that and how does it affect your operations?

Olivares has helped the government to establish the proper IP regulatory framework of the healthcare industry for a long time. Indeed, the Mexican Association of Pharmaceutical Research Industries (AMIIF) requested our services to represent them in the negotiation process to enter the TPP. We represented AMIIF in negotiation, lobbing and political activities; we have been involved in such process for more than two years. Even though the entrance of  Mexico to the TPP is highly crucial for the country, it is not 100 percent sure that such economical agreement is going to be finally a reality. Thus, we need to be forward-looking forecasting both possible scenarios.

On one hand, if the TPP actually becomes a reality for  Mexico, the country will benefit from the hard work that has been done during all the negotiation process to meet the TPP standards. Referring to the intellectual property chapter, it will be highly positive since IP protection standards will be maximized.

On the other hand, if the TPP does not finally happen for  Mexico, we should take advantage of all the work that has been done alongside such process to improve its laws in terms of better IP protection for instance.

I would like to highlight that Olivares is actively participating and helping the government to advance in this direction and to take advantage of the situation, regardless of the final outcome regarding the entrance of Mexico to the TPP.

We have perceived an epidemiologic transition in Mexico with more focus on chronic diseases. Such diseases can be only properly targeted through biotech or biosimilars treatments and an important milestone in the pharma industry has been the approval of the standard NOM 257 in December 2014, which regulates this area. How do you assess the regulatory framework in this area?

The first time that the biotechnological products were officially recognized in the applicable legislation, General Health Law was on June 2009, defining a "biologic/biotechnological product" as any substance that: has been manufactured by molecular biotechnology; has therapeutic, preventive or rehabilitative effects;

On October 2011, the Health Law Regulations were amended to establish the requirements to approve biologics and biocomparables, an area which was previously poorly regulated. After over 5 years of development, within the legal framework which included an emergency NOM, in 2014 the Mexican Official Standard Rule (NOM) NOM-257-SSA1-2014 regarding biotechnological products entered in force on February 2015.

The Health Law Regulations (Chapter VIII, Biotechnological products, Article 81) determines that recombinant proteins, monoclonal antibodies, synthetic peptides, nucleic acids synthetic or from plasmids are to be considered as biopharmaceuticals and biomedicaments.

Mexican Standard NOM-257-SSA1-2014 is supported by at least seven NOMs which are considered as the basis of technical and scientific evaluation presented during the medicament registration, such that it allows the Committee for New Molecules (CMN) and the subcommittee for evaluation of biotechnological products (SEPB) to issue an opinion related to:

New biotechnological medicaments during their research and/or development stage;

New biotechnological medicaments with their research and / or development stages completed;

Biotechnological medicaments biocomparable both in development stage and completed studies;

Biotechnological medicaments that already have a marketing authorization and are in the process of extension;

Classification of biotechnological medicaments as innovative or biocomparable, and

Definition ofreference medicaments.

Although the efficiency of the regulation is under test due to its recent enactment, there are few cases of strong criticism in the impact on the safety, efficacy and quality standards in biologics and biocomparables, until now, the main complaints have been due to the inobservance of exclusive rights, namely: patents and data package exclusivity.

Given the complexity of a biotechnological product, a central part is the follow-up of the behavior of the same in the population, so that the implementation of a pharmacovigilance program that allows the detection, identification, quantification, assessment and prevention of possible risks derived from the use of medicaments in humans, in other words is has to be prepared in accordance with Mexican Official Standard Rule NOM-220-SSA1-2012. This matter is now in vogue in Mexico due to a recent scandal in the acquisition of lower standard products in the State of Veracruz, where the State Ministry of Health has been accused to provide lower standard products to children with leukemia.

There are some issues unaddressed that are equally important for the industry, although, we trust that the authorities are working in having high and competitive standards for these types of products.

How is Olivares innovating to improve its service in terms of response times, cost efficiency and constantly developing its knowledge of client needs?

We have been highly successful in updating and innovating our operations to expand our business' umbrella but we have also heavily invested in enhancing our IT systems to improve the delivering of our services. Thus, we have not just been able to fulfill the dynamic needs of our clients but also to improve our efficiency ratios based on IT capabilities and synergies between our broad divisions. Innovation has permitted us to offer integral, efficient and effective solutions.

What are the key competitive advantages that make you the provider of choice both for the industry and the public institutions?

One of our main competitive advantage is clearly the unmatched knowledge within our teams, which can be argued are formed by the best attorneys and engineers in the country, but moreover, our people get to work on the most complex cases in the country and thus are always at the cutting edge of legal and business knowledge.

Our flexibility in terms of how we have reacted and adapted our operations to the national challenges have also been a key differentiator; as aforementioned, Olivares has disrupted the classic legal firm's business model creating one-stop shop solution as well as lowering costs through synergies and IT capabilities.

What are the key objectives that you would like to achieve in the upcoming three years?

As managing director of the firm, ensuring that we are always providing the best solution to our customers is one of my main priorities; I want to position Olivares as the legal partner of choice of all current and future clients. In this sense, we continue developing our strategy to add more value to our operations both in terms of quality and efficiency. Such a business model allows Olivares to enjoy a healthy but steady growth supported by its high performing teams.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions